Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Liberty Energy Inc. Class A common stock (LBRT) vs Moderna, Inc. (MRNA) Price & Performance

Liberty Energy Inc. Class A common stockTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Liberty Energy Inc. Class A common stock vs Moderna, Inc. — how do they compare? Liberty Energy Inc. Class A common stock trades at $19.08 (market cap $3.08B), while Moderna, Inc. trades at $224.92 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 25.5× Liberty Energy Inc. Class A common stock's market cap, and Liberty Energy Inc. Class A common stock pays a 1.91% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Energy Inc. Class A common stock for 1 Days and Moderna, Inc. for 59 Days on average.

LBRTMRNA
Market Cap
$3.08B$78.65B
Volume
4,917,31537,373,437
Sector
EnergyHealth
52-Week High
$33.93$203.46
52-Week Low
$11.94$22.36
Typical Hold Time
1 Days59 Days
Enterprise Value
$4.13B$74.80B
Dividend Yield
1.91%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Liberty Energy Inc. Class A common stock

No Aura AI signal available yet.

Moderna, Inc.

Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.

Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LBRT

No sentiment data available yet.

MRNA
53% Buy47% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Liberty Energy Inc. Class A common stock

Liberty Energy provides completion services and technologies for onshore oil, natural gas, and geothermal producers in North America. It also offers distributed power and energy-storage solutions through Liberty Power Innovations.

Read more on LBRT →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA →